Labetuzumab Y-90

Drug Profile

Labetuzumab Y-90

Alternative Names: Anti-CEA monoclonal antibody MN 14-Y-90; CEA-Cide-Y-90; hCEA-Y-90; IMMU-101

Latest Information Update: 19 Jan 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 23 Jun 2004 Immunomedics has completed two phase I trials in colorectal and pancreatic cancers in the US
  • 23 Apr 2002 Phase-I/II clinical trials in Colorectal cancer in USA (IV-infusion)
  • 23 Apr 2002 Phase-I/II clinical trials in Pancreatic cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top